Signal #134592 · SEC 8-K

$PCVX SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $PCVX filing catalyst

Why did $PCVX trigger an AI stock catalyst alert?

$PCVX triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: Vaxcyte Reports Positive VAX-31 Phase 3 OPUS-1 Data and Q3 2026 Results. Key points: - VAX-31 met all prespecified primary endpoints in pivotal Phase 3 OPUS-1 adult trial with a safety profile similar to PCV20/PCV21. - Cash, cash equivalents, and investments stood at $2.26B as of Sept 30, 2026, excluding ~$1.1B net proceeds from October offerings; BLA planned for H1 2028. - Q3 2026 net loss expanded to $297.1M from $212.8M in Q3 2025 due to elevated Phase 3 R&D spend.

How did $PCVX stock react after the SEC filing?

After the SEC 8-K for $PCVX, observed market reaction: T0 price $65.68. Past moves do not guarantee future results.

Where can I get real-time $PCVX SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $PCVX via Telegram and the VIP Web Terminal from €10/month.

$PCVX

$PCVX – Vaxcyte Reports Positive VAX-31 Phase 3 OPUS-1 Data and Q3 2026 Results

Vaxcyte, Inc.

2026-11-04 00:00:00 UTC · SEC 8-K · All $PCVX

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+6.5 / 10)

VAX-31 met all prespecified primary endpoints in pivotal Phase 3 OPUS-1 adult trial with a safety profile similar to PCV20/PCV21.
Cash, cash equivalents, and investments stood at $2.26B as of Sept 30, 2026, excluding ~$1.1B net proceeds from October offerings; BLA planned for H1 2028.
Q3 2026 net loss expanded to $297.1M from $212.8M in Q3 2025 due to elevated Phase 3 R&D spend.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →